Interestingly, in a model of HFD in mice, administration of the non-selective MAO-A/MAO-B inhibitor phenelzine normalized metabolic alterations, including subcutaneous and hepatic fat, hypertriglyceridemia, insulin resistance and markers of oxidative stress [113]. Here, MAOA is linked to Insulin resistance.